Primary AML cell sample data
. | Expression . | . | . | . | . | . | Efflux . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assay . | CD33, mean . | pBzR, mean ± SD . | Pgp, mean . | MRP1, mean . | Bcl-2, mean . | Bcl-xL, mean . | DiOC2(3), mean . | CDCF, mean . | ||||||
| PX1 | 76 | 1681 ± 113 | 6.41 | 19.23 | nd | nd | 15.030 | 2.101 | ||||||
| PX2 | 205 | 3331 ± 260 | 4.07 | 35.82 | 0.34 | 0.40 | 1.326 | 5.829 | ||||||
| PX3 | 43 | 2996 ± 150 | −2.79 | 14.66 | 0.66 | 0.53 | 1.155 | 1.167 | ||||||
| PX4 | 199 | nd | −1.46 | 2.00 | nd | nd | 1.045 | 2.299 | ||||||
| PX5 | 151 | 1944 ± 42 | 2.75 | 32.22 | 0.71 | 0.58 | 47.349 | 2.144 | ||||||
| PX6 | 51 | 1227 ± 87 | 0.49 | 22.67 | 11.13 | 0.76 | 1.238 | 1.999 | ||||||
| PX7 | 92 | nd | 0.02 | 24.75 | nd | nd | 1.101 | 3.185 | ||||||
| PX8 | 224 | nd | 0.15 | 35.44 | nd | nd | 0.946 | 1.639 | ||||||
| PX9 | 8 | 729 ± 21 | 1.11 | 26.30 | 0.71 | 0.55 | 5.826 | 2.465 | ||||||
. | Expression . | . | . | . | . | . | Efflux . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assay . | CD33, mean . | pBzR, mean ± SD . | Pgp, mean . | MRP1, mean . | Bcl-2, mean . | Bcl-xL, mean . | DiOC2(3), mean . | CDCF, mean . | ||||||
| PX1 | 76 | 1681 ± 113 | 6.41 | 19.23 | nd | nd | 15.030 | 2.101 | ||||||
| PX2 | 205 | 3331 ± 260 | 4.07 | 35.82 | 0.34 | 0.40 | 1.326 | 5.829 | ||||||
| PX3 | 43 | 2996 ± 150 | −2.79 | 14.66 | 0.66 | 0.53 | 1.155 | 1.167 | ||||||
| PX4 | 199 | nd | −1.46 | 2.00 | nd | nd | 1.045 | 2.299 | ||||||
| PX5 | 151 | 1944 ± 42 | 2.75 | 32.22 | 0.71 | 0.58 | 47.349 | 2.144 | ||||||
| PX6 | 51 | 1227 ± 87 | 0.49 | 22.67 | 11.13 | 0.76 | 1.238 | 1.999 | ||||||
| PX7 | 92 | nd | 0.02 | 24.75 | nd | nd | 1.101 | 3.185 | ||||||
| PX8 | 224 | nd | 0.15 | 35.44 | nd | nd | 0.946 | 1.639 | ||||||
| PX9 | 8 | 729 ± 21 | 1.11 | 26.30 | 0.71 | 0.55 | 5.826 | 2.465 | ||||||
Data are presented as in Table 1, except antiapoptotic protein expression was measured by specific immunostaining and is expressed relative to HL-60 intra-assay controls. HL-60/Bcl-2 cells showed 12.05 ± 1.26-fold more Bcl-2 immunostaining than HL-60 cells, and HL-60/Bcl-xL cells showed 1.16 ± 0.08-fold more Bcl-xL immunostaining than HL-60 cells in the same assays. Cell materials from patients 7 and 8 were insufficient to perform PK11195 binding assays or antiapoptotic protein immunostaining. Toxicity data for these primary AML cell samples are presented in Figure 5.
nd indicates not done.